key: cord-0944353-nles7ymd
authors: Zuo, Y.; Estes, S. K.; Gandhi, A. A.; Yalavarthi, S.; Ali, R. A.; Shi, H.; Sule, G.; Gockman, K.; Madison, J. A.; Zuo, M.; Woodard, W.; Lezak, S. P.; Lugogo, N. L.; Kanthi, Y.; Knight, J. S.
title: Prothrombotic antiphospholipid antibodies in COVID-19
date: 2020-06-17
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2020.06.15.20131607
sha: f55fd8d630f9f86ef463589b4c1b29cf4f6ace8c
doc_id: 944353
cord_uid: nles7ymd

Patients with coronavirus disease 19 (COVID-19) are at high risk for thrombotic arterial and venous occlusions. At the same time, lung histopathology often reveals fibrin-based occlusion of small vessels in patients who succumb to the disease. Antiphospholipid syndrome (APS) is an acquired and potentially life-threatening thrombophilia in which patients develop pathogenic autoantibodies (aPL) targeting phospholipids and phospholipid-binding proteins. Small case series have recently detected aPL in patients with COVID-19. Here, we measured eight types of aPL (anticardiolipin IgG/IgM/IgA, anti-beta-2 glycoprotein I IgG/IgM/IgA, and anti- phosphatidylserine/prothrombin (PS/PT) IgG/IgM) in the sera of 172 patients hospitalized with COVID-19. We detected anticardiolipin IgM antibodies in 23%, anti-PS/PT IgG in 24%, and anti-PS/PT IgM in 18%. Any aPL was present in 52% of patients using the manufacturer's threshold and in 30% using a more stringent cutoff (>40 units). Higher levels of aPL were associated with neutrophil hyperactivity (including the release of neutrophil extracellular traps/NETs), higher platelet count, more severe respiratory disease, and lower glomerular filtration rates. Similar to patients with known and longstanding APS, IgG fractions isolated from patients with COVID-19 promoted NET release from control neutrophils. Furthermore, injection of these COVID-19 IgG fractions into mice accelerated venous thrombosis. Taken together, these studies suggest that a significant percentage of patients with COVID-19 become at least transiently positive for aPL and that these aPL are potentially pathogenic.

Abnormal coagulation parameters such as elevations in D-dimer and fibrin(ogen) degradation products correlate with COVID-19 severity 1,2 . D-dimer, in particular, is an independent risk factor for death 1, [3] [4] [5] . Early descriptions of the COVID-19 coagulopathy identified it as disseminated intravascular coagulation (DIC). However, most patients maintain normal levels of coagulation factors, fibrinogen, and platelets suggesting that COVID-19 induces a unique prothrombotic coagulopathy distinct from traditional descriptions of sepsis-induced coagulopathy 6, 7 . There are now increasing reports of VTE in patients with COVID-19 8, 9 . This observation is despite concerns regarding under-diagnosis given baseline elevations in the sensitive biomarker Ddimer, as well as pragmatic challenges in obtaining diagnostic imaging while patients are in isolation. Arterial thrombosis including strokes and myocardial infarctions have also been described 9, 10 . Histopathology of lung specimens from patients with severe disease show not only characteristic findings of ARDS but also evidence of fibrin-based occlusion of small vessels [11] [12] [13] . There are several (possibly synergistic) mechanisms by which SARS-CoV-2 infection may results in microvascular and macrovascular thrombosis including a cytokine storm that activates leukocytes, endothelium, and platelets; hypoxic vaso-occlusion; and direct activation of cells by viral transduction. Furthermore, many patients hospitalized with have high levels of neutrophil extracellular traps (NETs) in their blood 14 , and these inflammatory cell remnants may also contribute to the prothrombotic milieu 15 .

Antiphospholipid syndrome (APS) is an acquired thrombophilia, affecting at least 1-in-2000 individuals 16 . Patients form autoantibodies to phospholipids and phospholipid-binding proteins such as prothrombin and beta-2-glycoprotein I (β2GPI). These autoantibodies engage cell surfaces, where they activate endothelial cells, platelets, and neutrophils 17, 18 , thereby tipping the blood-endothelium interface toward thrombosis. A defining feature of APS is its ability to promote thrombosis in vascular beds of all sizes, including both arterial and venous circuits. The catastrophic variant of APS is frequently fatal, and bears some similarities to the diffuse coagulopathy seen in patients with COVID-19 19 . Classification criteria for APS (last updated in 2006) seek persistently positive testing for anticardiolipin or anti-β2GPI antibodies 20 . Lupus anticoagulant testing (a functional assay that screens for aPL based on their paradoxical ability to prolong in vitro clotting assays) is also included in the criteria and detects a variety of species of aPL including anti-phosphatidylserine/prothrombin (anti-PS/PT) 21 .

Reports of antiphospholipid antibodies (aPL) in COVID-19 and their possible relationship to thrombosis have begun to emerge in small case reports and series [22] [23] [24] [25] . While viral infections are well-known triggers of transient aPL [26] [27] [28] [29] , the extent to which these antibodies are pathogenic has never been well defined. Human immunodeficiency virus, hepatitis C virus, and parvovirus B19 have all been associated with aPL 28 (typically positive anticardiolipin IgG or IgM) with molecular mimicry suggested as a potential mechanism 30, 31 . Interestingly, a recent systematic review suggested that one-third of individuals who develop a thrombotic event and aPL in association with a viral infection will have durable positivity of these aPL over at least several months and thereby meet classification criteria for APS 28 .

Here, we endeavored to test several types of aPL in a large cohort of patients hospitalized with COVID-19. We also asked whether purified IgG fractions from these patients had prothrombotic properties in vitro and in vivo. Table 1) were evaluated for eight different types of aPL. Of the 172 patients, 19% have died and 8% remain in the hospital at the time of this writing. Eighty-nine patients tested positive for at least one type of aPL based on the manufacturer's cut-off, representing 52% of the entire cohort ( Table 1) . Lupus anticoagulant testing was not performed given lack of access to fresh plasma samples. Among the various aPL tested, anti-PS/PT IgG had the highest prevalence (24%), followed by anticardiolipin IgM (23%) and anti-PS/PT IgM (18%). Forty-one patients (24%) were positive for more than one type of aPL and 13 (8%) were positive for more than two. Fifty-two patients (30%) had at least one moderate-to high-titer aPL ( Table 1) . Thirty-five patients had sera from multiple time points tested for aPL and those results are presented in Supplementary Figure 1 . In summary, any positive aPL was detected in 52% of patients hospitalized for COVID-19, with approximately two-thirds of those being detected at moderate-to-high titers. The majority of positives were associated with three antibodies: anti-PS/PT IgG, anticardiolipin IgM, and anti-PS/PT IgM.

Clinical correlations of COVID-19-associated aPL. We next asked whether the presence of aPL associated with various clinical parameters. Specifically, we assessed potential correlations with SpO2/FiO2 ratio (i.e., oxygenation efficiency), C-reactive protein, D-dimer, platelet count, absolute neutrophil count, calprotectin (a marker of neutrophil activation), and myeloperoxidase-DNA complexes (a marker of NETs) ( Table 2) . Levels of anticardiolipin IgM were significantly correlated with all clinical markers tested ( Table 2) . Of the clinical markers tested, neutrophil activation (calprotectin) most consistently associated with various different aPL ( Table 2) . We also assessed a previously devised scoring tool (aPL-S), which integrates and prioritizes data from the various aPL types tested (see Methods) 32 . aPL-S demonstrated a positive correlation with platelet counts, neutrophil activation, and NETs ( Table 2) . We then examined various clinical parameters as they related to positive/negative aPL cutoffs. Positive testing for any aPL was associated with higher levels of calprotectin and lower estimated glomerular filtration rate (eGFR) (Figure 1A-C) . These differences were also observed when comparing patients with positive anti-PS/PT to the remainder of the cohort (Figure 1D -F). Average peak troponin and peak D-dimer were both higher in patients with aPL, although group comparisons did not reach statistical significance (Figure 1) . Taken together, it appears that COVID-19-associated aPL track with various clinical parameters, especially neutrophil activation and impaired renal function.

has revealed that one prothrombotic function of aPL in patients with APS is to trigger NET release 17, 33 . Given that we recently detected elevated levels of NETs in COVID-19 patients 14 , we reasoned that IgG fractions purified from patients with COVID-19 might be able to trigger NET release. We selected two COVID-19 patients with high anti-β2GPI IgG, two with high anti-PS/PT IgG, and two without any positive aPL. From these patients, we purified total IgG and tested alongside IgG pooled from two patients with active catastrophic antiphospholipid syndrome (CAPS), as well as a separate pool from five patients with longstanding triple-positive APS (positive testing for anticardiolipin, anti-β2GPI, and lupus anticoagulant). As compared with unstimulated neutrophils, COVID-19 IgG samples positive for aPL doubled NET release, similar to CAPS and APS samples (Figure 2A) . Representative COVID-19 IgG-induced NETs are shown in Figure 2B . In summary, it appears that purified IgG fractions from aPL-positive COVID-19 patients promote NET release similarly to IgG isolated from individuals with established APS.

We have previously reported that IgG isolated from patients with either CAPS or triple-positive APS accelerates large-vein thrombosis in various mouse models of inferior vena cava thrombosis [33] [34] [35] . Here, we asked whether COVID-19 IgG might behave similarly to enhance thrombosis under such conditions. In a model that activates the endothelium by local electrolysis-mediated free radicals ( Figure 3A All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131607 doi: medRxiv preprint DISCUSSION aPL are a heterogeneous group of autoantibodies that play an important role in the pathogenesis of APS via their interactions with plasma protein such as β2GPI, prothrombin, thrombomodulin, plasminogen, antithrombin III, protein C, protein S, annexin II, annexin V, and likely others [10] [11] [12] [13] [14] [15] . The association between viral infection and the development of aPL has long been suggested 27, 28 , with anticardiolipin IgG and IgM (lacking anti-β2GPI activity) most commonly reported 36 . While the clinical significance of these antibodies remains to be fully defined, a recent review of 163 published cases of virus-associated aPL found thrombotic events in 116 28 . While acknowledging the possibility of sampling and publication bias, these data suggest that even if the antibodies are transient, they may still have prothrombotic potential-including in the patients described here with severe cases of COVID-19. Whether similar findings would extend to patients with less symptomatic COVID-19 presentations-some of whom may experience thrombotic events-awaits further study.

The most severe presentation of APS is its catastrophic variant known as CAPS, which fortunately impacts only a minority of APS patients, typically at times of stress such as infection, surgery, or anticoagulation withdrawal 37 . CAPS involves derangements of both inflammatory and thrombotic pathways and impacts multiple organs in the body simultaneously 37 . In the largest series of CAPS patients assembled, the most commonly affected organs were kidneys (73%), lungs (60%), brain (56%), heart (50%), and skin (47%) 38 . While multi-organ failure may certainly complicate severe cases of COVID-19, the lungs are almost always the most severely affected. We speculate that local immune stimulation from viral infection (including potentially the infection of endothelial cells) could synergize with circulating aPL and thereby lead to a particularly severe thromboinflammatory insult to the lungs of COVID-19 patients.

Many studies from the general thrombosis literature have revealed that activated neutrophils, and in particular NET formation, contribute to the propagation of thrombi affecting arterial, venous, and microscopic vascular beds 39, 40 . NETs have also been recently implicated in the pathogenesis of APS. In 2015, our group reported that sera from APS patients, as well as purified aPL, trigger neutrophils to release NETs 17 . The potential in vivo relevance of this observation has been confirmed in mouse models of aPL-mediated large-vein thrombosis in which either depletion of neutrophils or digestion of NETs is protective 33 . Neutrophils from APS patients also appear to have increased adhesive potential, which is dependent upon the activated form of integrin Mac-1. This pro-adhesive phenotype amplifies neutrophil-endothelium All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131607 doi: medRxiv preprint interactions, potentiates NET formation, and potentially lowers the threshold for thrombosis 33 .

Therapies that target NET formation have the potential to treat thrombotic diseases 30 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . may contain aPL or other autoantibodies, in addition to protective anti-COVID-19 antibodies, is another potential area for future investigation.

This study has several limitations. We did not have access to the fresh plasma that would be required for lupus anticoagulant testing (which would have provided additional context and risk stratification to the aPL profiling). We speculate that many of the patients with positive anti-PS/PT would have displayed a lupus anticoagulant phenotype-as reported recently 21 -but proving that will require further study and prospective access to samples. We were also not able to define a clear link between circulating aPL and large artery/vein thrombosis. Eleven patients in our cohort had thrombotic events and 55% of those were positive for aPL. It should be noted that aggressive anticoagulation has been regularly employed at our institution including many patients treated prophylactically with therapeutic doses of anticoagulation prophylactically. It should also be noted that aPL were not tested on a defined hospital day, but rather when a sample became available to the research laboratory. Future studies should endeavor to systematically track aPL over the full course of a hospitalization, and perhaps especially at and after the time of discharge. In the meantime, and as we await definitive antiviral and immunologic solutions to the current pandemic, we posit that testing aPL, including anti-PS/PT, may lead to improved risk stratification and personalization of treatment.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Human neutrophil purification and NETosis assays. Collection of healthy human blood was approved by the University of Michigan IRB (HUM00044257). For neutrophil preparation, blood from healthy volunteers was collected into heparin tubes by standard phlebotomy techniques.

The anticoagulated blood was then fractionated by density-gradient centrifugation using Ficoll-Paque Plus (GE Healthcare). Neutrophils were further purified by dextran sedimentation of the red blood cell layer, before lysing residual red blood cells with 0.2% sodium chloride. Neutrophil preparations were at least 95% pure as confirmed by both flow cytometry and nuclear morphology. To assess NETosis, complementary approaches were utilized. For the NETassociated MPO assay, neutrophils were resuspended in RPMI media (Gibco) supplemented with 0.5% bovine serum albumin (BSA, Sigma) and 0.5% fetal bovine serum (Gibco), which had been heat-inactivated at 56°C. Neutrophils (1x10 5 /well) were then incubated in 96-well plates with 10 µg/ml human IgG for 3 hours. To collect NET-associated MPO, the culture media was discarded (to remove any soluble MPO) and replaced with 100 µL of RPMI supplemented with 5 U/ml Micrococcal nuclease (Thermo Fischer Scientific). After 10 minutes at 37 º C, digestion of NETs was stopped with 10 mM EDTA. Supernatants were transferred to a v-shaped 96 well All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . plate, and centrifuged at 350xg for 5 minutes to remove debris. Supernatants were then transferred into a new plate. To measure MPO activity, an equal volume of 3,3',5,5'-Tetramethylbenzidine (TMB) substrate (1 mg ml -1 , Thermo Fischer Scientific) was added to each well. After 10 minutes of incubation in the dark, the reaction was stopped by the addition of 50 µL of 1 mM sulfuric acid. Absorbance was measured at 450 nm using a Cytation 5 Cell Imaging Multi-Mode Reader. For immunofluorescence microscopy, 1.5 x 10 5 neutrophils were seeded onto coverslips coated with 0.001% poly-L-lysine (Sigma) and fixed with 4% paraformaldehyde. In some experiments, cells were then permeabilized with 0.1% Triton-X for 15 minutes at room temperature. Blocking was with 1% bovine serum albumin. The primary antibody was against neutrophil elastase (Abcam 21595, diluted 1:100), and the FITC- In vivo venous thrombosis. To model large-vein thrombosis, we employed procedures that we have utilized previously 33, 35, 48 . For the stenosis model, a laparotomy was performed under anesthesia. After exposure of the IVC, any lateral branches were ligated using 7-0 Prolene suture (back branches remained patent). A ligature was then fastened around the IVC over a blunted 30-gauge needle (which served as a spacer). After removal of the spacer, the abdomen was closed. Before recovery from anesthesia, mice received a single intravenous injection of human IgG (500 µg). 24 hours later, mice were humanely euthanized, blood was collected, and thrombus characteristics were measured. The electrolytic model was performed as described 49 .

Briefly, after exposure of the IVC, any lateral branches were ligated using 7-0 Prolene suture (back branches remained patent). A 30-gauge silver-coated copper wire (KY-30-1-GRN, Electrospec) with exposed copper wire at the end was placed inside a 25-gauge needle, which was inserted into the IVC and positioned against the anterior wall (where it functioned as the anode). Another needle was implanted subcutaneously, completing the circuit (cathode). A constant current of 250 μA was applied for 15 minutes. The current was supplied by the voltage-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06. 15.20131607 doi: medRxiv preprint to-current converter that is described in detail in the reference 49 . After removal of the needle, the abdomen was closed. Before recovery from anesthesia, mice received a single intravenous injection of human IgG (500 µg). 24 hours later, mice were humanely euthanized, blood was collected, and thrombus characteristics were measured.

Statistical analysis. Normally-distributed data were analyzed by two-sided t test and skewed data were analyzed by Mann-Whitney test. Comparisons of more than two groups were analyzed by one-way ANOVA with correction for multiple comparisons by Dunnett's method.

Data analysis was with GraphPad Prism software version 8. Correlations were tested by Spearman's correlation coefficient. Statistical significance was defined as p<0.05 unless stated otherwise.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131607 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131607 doi: medRxiv preprint some mice included in B-C were tested for NET remnants as measured by myeloperoxidase-DNA ELISA. F, Model of thrombus initiation in the IVC by fixed stenosis. G-H, Mice were treated with COVID-19 IgG as indicated and thrombus size was determined 24 hours after stenosis. I, Representative thrombi from G-H. J, Sera from some mice included in G-H were tested for NET remnants. Comparisons were by either one-way ANOVA with correction for multiple comparisons by Dunnett's method (B, C, E) or unpaired t test (G, H, J); *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131607 doi: medRxiv preprint

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Clinical Characteristics of Coronavirus Disease 2019 in China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation

Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Neutrophil extracellular traps in COVID-19

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

Treatment of thrombotic antiphospholipid syndrome in adults and children

Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome

Antiphospholipid syndrome: a clinical perspective

Treatment of catastrophic antiphospholipid syndrome

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study

Severe COVID-19 infection associated with endothelial activation

Clinically significant anticardiolipin antibodies associated with COVID-19

Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis

Primary', 'secondary' and other variants of the antiphospholipid syndrome

Systematic review of case reports of antiphospholipid syndrome following infection

COVID-19) Infection Associated With Antiphospholipid Antibodies and Four-Extremity Deep Vein thrombosis in a Previously Healthy Female

Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome

Pathogenic Autoreactive T and B Cells Cross-React with Mimotopes Expressed by a Common Human Gut Commensal to Trigger Autoimmunity

Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events

In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis

Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome

Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target

A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection

The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review

Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry

The role of neutrophils in thrombosis

Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer-Associated Thrombosis

New (re)Purpose for an old drug: purinergic receptor blockade may extinguish the COVID-19 thrombo-inflammatory firestorm

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

Seronegative antiphospholipid syndrome

IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus

Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review

Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients

Netting neutrophils in autoimmune small-vessel vasculitis

Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1beta-driven venous thrombosis

Update on the electrolytic IVC model for pre-clinical studies of venous thrombosis